eranicle/iStock via Getty Images
A phase 2b trial of Viking Therapeutics’ (NASDAQ:VKTX) VK2809 found that those on the medicine saw statistically significant reductions in liver fat, meeting the primary endpoint.
At week 12, the mean relative change from baseline ranged from 37% to 55%. The response rate
